Ardea Biosciences (RDEA) Completes Common Stock Offering, Gross Proceeds $166.2 Million
Tweet
Share
E-mailGet Alerts RDEA Hot Sheet
Join SI Premium – FREE
Ardea Biosciences, Inc. (NASDAQ: RDEA) announced the completion of an underwritten public offering of 9,775,000 shares of its common stock, including 1,275,000 shares sold pursuant to the full exercise of an over-allotment option previously granted to the underwriters.
All of the shares were offered by Ardea at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering were approximately $166.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ardea.
Ardea anticipates using the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to Phase 3 clinical trials of lesinurad, capital expenditures, working capital, and general and administrative expenses.
All of the shares were offered by Ardea at a price to the public of $17.00 per share. The gross proceeds to Ardea from this offering were approximately $166.2 million, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Ardea.
Ardea anticipates using the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to Phase 3 clinical trials of lesinurad, capital expenditures, working capital, and general and administrative expenses.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- DeFi Development Corp. plans $20M preferred stock offering
- Simply Solventless files Q1 financials, expects management trade ban lifted soon
- StrategX extends private placement deadline to September 30
Create E-mail Alert Related Categories
Equity OfferingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
